Leqembi, Eisai and Biogen’s amyloid-targeted antibody therapy, has earned FDA approval for the treatment of Alzheimer’s disease.| Alzheimer's News Today
Learn more about Biogen's strategic realignment from Aduhelm's controversy to Leqembi's promise in Alzheimer's treatment.| Labiotech.eu